Niagen BioScience
Smarter science. Better aging. Pioneering NAD+ research.
Niagen BioScience Instagram
Niagen BioScience Instagram
Niagen BioScience Facebook
Niagen BioScience Facebook
Niagen BioScience LinkedIn
Niagen BioScience LinkedIn
Niagen BioScience YouTube
Niagen BioScience YouTube
Niagen BioScience X
Niagen BioScience X
Fireside Chat with Niagen Bioscience – Longevity as the Next Consumer Revolution
Fireside Chat with Niagen Bioscience – Longevity as the Next Consumer Revolution
Fireside Chat with TruNiagen – The Power of Brand and Cultural Impact
Cannes Lions 2026 | Monks
Cannes Lions 2026 | Monks
Join us at Cannes 2026 to see how orchestration, powered by agentic workflows, turns marketing into a high-velocity growth engine.
East Coast IDEAS Investor Conference Live Stream
East Coast IDEAS Investor Conference Live Stream
East Coast IDEAS Conference
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. Niagen Bioscience CEO, Rob Fried, will present on Thursday, June 11, from 2:40 - 3:15 PM ET in the Presenting Room. The presentation will be livestreamed and can be accessed through the conference host’s main website: www.threepartadvisors.com/east-coast . CFO Ozan Pamir will also attend to host one-on-one meetings with institutional investors at the conference. If you would like to schedule a one-on-one meeting with the
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program , reflecting the Company’s name evolution with a focus on advancing the understanding and applications of NAD+ through its flagship ingredient, Niagen ® (patented nicotinamide riboside, or NR), the most efficient, effective, and highest-quality NAD+ booster. Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science “The Niagen Research Program
There’s Good News and Bad News About NAD+, the Buzziest Wellness Supplement
There’s Good News and Bad News About NAD+, the Buzziest Wellness Supplement
NAD exists in a space somewhere between legitimate science, luxury wellness treatment, and social media trend
Niagen launches telehealth NAD+ injection platform
Niagen launches telehealth NAD+ injection platform
Prescription-only Niagen kit brings at-home delivery model to NAD+ therapies, combining telehealth access with clinician oversight.
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location : Jazz at Lincoln Center’s Frederick P. Rose Hall Date : May 12, 2026 Format : Emerging Company Pavilion, a curated showcase of 8-10 select companies Management : Ozan Pamir, CFO 4th Annual Benchmark Consumer One-On-One Conference Location : New York Athletic Club Date : May 19, 2026 Format : One-on-one meetings Management : Rob Fried, CEO, and Ozan Pamir, CFO If you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email Niagen@KCSA.com . For additional information on Niagen Bioscience, visit www.niagenbioscience.com . About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE) is
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, including a $4.8 million gain on the divestiture of the Analytical Reference Standards and Services operating segment. Basic and diluted earnings per share were $0.08 and $0.07, respectively. Adjusted EBITDA, a non-GAAP measure, was $3.8 million. Working capital (1) increased by $5.4 million quarter-over-quarter. Used $1.2 million in operating cash flow during the
The new era of life sciences
The new era of life sciences
Despite headwinds, the U.S. life sciences industry continues to yield impressive results, leveraging technology for earlier diagnosis and even prevention. Read more about the latest industry dynamics and advances. (Partner Content)
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
New telehealth platform introduces prescription-only Niagen At-Home Injection Kit, expanding access to pharmaceutical-grade NAD+ support for cellular and tissue health delivered directly to eligible patients' doors Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its clinician-directed telehealth platform under Niagen™ Plus , enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade Niagen ® (patented nicotinamide riboside chloride, NRCl) from home with the first-of-its-kind Niagen® At-Home Injection Kit . The launch marks Niagen Bioscience's first direct-to-client access model and introduces at-home subcutaneous administration, eliminating the need for an in-person doctor’s or drug store visit, extending the reach of Niagen Plus beyond clinic visits. Niagen Bioscience launches Niagen Plus telehealth platform, unveiling
Inside Tru Niagen’s Expansion Into NAD+ Beauty And Skincare
Inside Tru Niagen’s Expansion Into NAD+ Beauty And Skincare
Known for its patented nicotinamide riboside (NR), Niagen Bioscience is entering skincare and beauty with efficacious NAD+ solutions
Niagen Bioscience innovating NAD+-based therapies from healthy aging to pediatric orphan diseases - BioTuesdays
Niagen Bioscience innovating NAD+-based therapies from healthy aging to pediatric orphan diseases - BioTuesdays
By Melane Sampson Robert Fried, CEO of Niagen Bioscience Niagen Bioscience (NASDAQ: NAGE) is pioneering the research and development of nicotinamide
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Partnership unlocks Olympia’s established clinic network for Niagen Plus, expands pharmaceutical-grade Niagen supply chain, and brings liquid compounded vials to market Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia Pharmaceuticals , a state-of-the-art U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen ® (patented nicotinamide riboside, NR) for the Company’s Niagen Plus™ intravenous and injectable products. Olympia Pharmaceuticals joins Wells Pharma of Houston, diversifying the Company’s 503B network and supply chain capabilities to support continued growth across its clinic footprint and expand access to the Company’s innovative Niagen Plus product pipeline. "We anticipate that Olympia will play an important role in meeting the growing demand for Niagen IV and Niagen injections,” said
Live Foreverish Podcast Episode
Podcast
·
Podcast
Live Foreverish Podcast Episode
Podcast Episode · Live Foreverish · March 9 · 53m
What Is Nicotinamide Riboside (NR)? How It Increases NAD Levels - Los Angeles Times
What Is Nicotinamide Riboside (NR)? How It Increases NAD Levels - Los Angeles Times
Niagen Bioscience CEO Rob Fried explains nicotinamide riboside (NR), Tru Niagen, and new at-home injections, IVs, and NAD+ formats.
How Tru Niagen Built Niagen Bioscience’s NAD+ Longevity Business - Los Angeles Times
How Tru Niagen Built Niagen Bioscience’s NAD+ Longevity Business - Los Angeles Times
CEO Rob Fried reveals Niagen Bioscience’s NAD+ growth strategy, from Tru Niagen to their upcoming telehealth launch.
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026. Investor Conference Call: A live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience’s first quarter financial results and provide a general business update. To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of Niagen Bioscience’s website at www.niagenbioscience.com . The toll-free dial-in information for this call is 1 (833) 461-5787
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
NR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience’s leadership in NAD+ science and ingredient quality Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Company’s flagship ingredient, Niagen ® , now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This monograph reflects the scientific rigor behind Niagen and establishes a global benchmark for what high-quality NRCl should look like in dietary supplements, limiting adulterants and contaminants. Rob Fried, Chief Executive Officer of Niagen Bioscience, said, “This monograph is a meaningful development for the broader NAD+ supplement industry because NR now has a published pharmacopeial standard, while NMN and NAD+ do not. It
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus’ footprint Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced OneSpaWorld (NASDAQ: OSW) as the newest Niagen Plus ™ provider, engaged to offer pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Marking Niagen Bioscience’s first cruise ship clinic partnership, this collaboration brings Niagen IV to guests at sea. Niagen IV launches across Medi-Spa clinics on high-end cruise ships Rob Fried, CEO of Niagen Bioscience, commented, “OneSpaWorld opens a new premium channel at sea, strengthens our rapidly expanding Niagen Plus clinic footprint, and supports our strategy to scale Niagen IV and injections outside of the U.S.” This partnership extends Niagen Bioscience’s fast-growing clinical channel for Niagen Plus, with Niagen IV and injections
NAD for Health: Opportunities & Challenges
NAD for Health: Opportunities & Challenges
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience to Present at the 38th Annual ROTH Conference
Niagen Bioscience to Present at the 38th Annual ROTH Conference
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting - PubMed
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting - PubMed
How To Boost NAD Levels To Fight Inflammation, Improve Recovery, and Slow Aging | Dr. Charles Brenner
How To Boost NAD Levels To Fight Inflammation, Improve Recovery, and Slow Aging | Dr. Charles Brenner
Going the Distance: US Olympic… - Pregnantish - Apple Podcasts
Podcast
·
Podcast
Going the Distance: US Olympic… - Pregnantish - Apple Podcasts
The divergent effects of nicotinamide riboside and high-intensity exercise training on skeletal muscle epigenetic aging
The divergent effects of nicotinamide riboside and high-intensity exercise training on skeletal muscle epigenetic aging
The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation: iScience
The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation: iScience
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
Podcast
·
Podcast
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
5 Supplements Women over 50 Should Consider
5 Supplements Women over 50 Should Consider
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
Podcast
·
Podcast
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
The Best Products from the Most Popular Wellness Brands of 2025 - Athletech News
The Best Products from the Most Popular Wellness Brands of 2025 - Athletech News
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
BlueMatrix
BlueMatrix
CRN Announces Board of Directors Election Results; Association Leadership in Place to Address 2026 Challenges and Opportunities for the Dietary Supplement and Functional Food Industry | Council for Responsible Nutrition
CRN Announces Board of Directors Election Results; Association Leadership in Place to Address 2026 Challenges and Opportunities for the Dietary Supplement and Functional Food Industry | Council for Responsible Nutrition
The Wild West World Of Supplements—What Consumers Should Know
The Wild West World Of Supplements—What Consumers Should Know
Exclusive | Buzzy NAD+ treatment boosts energy, better sleep and recovery | New York Post
Exclusive | Buzzy NAD+ treatment boosts energy, better sleep and recovery | New York Post
Long Covid Podcast- Cellular Recharge: Can N…
Podcast
·
Podcast
Long Covid Podcast- Cellular Recharge: Can N…
Exclusive: NAD+ supplement leader Tru Niagen enters the beauty supplement market, targeting the ‘much younger’ wellness consumer
Exclusive: NAD+ supplement leader Tru Niagen enters the beauty supplement market, targeting the ‘much younger’ wellness consumer
Healthcare Practitioner Webinar Series – Episode 30 - Exploring Niagen in Individuals with Long COVID Symptoms - Demio
Healthcare Practitioner Webinar Series – Episode 30 - Exploring Niagen in Individuals with Long COVID Symptoms - Demio
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial - eClinicalMedicine
Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial - eClinicalMedicine
Niagen Bioscience Announces $10 Million Share Repurchase Program
Niagen Bioscience Announces $10 Million Share Repurchase Program
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
NAD+ market analysis: From hype to reality check
NAD+ market analysis: From hype to reality check
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
niagenbioscience.com
niagenbioscience.com
truniagen.com
truniagen.com
Tru Niagen Instagram
Tru Niagen Instagram
Tru Niagen TikTok
Tru Niagen TikTok
Tru Niagen Facebook
Tru Niagen Facebook
Tru Niagen YouTube
Tru Niagen YouTube
Tru Niagen on X
Tru Niagen on X
niagenplus.com
niagenplus.com
Niagen Plus Instagram
Niagen Plus Instagram
Niagen Plus TikTok
Niagen Plus TikTok
Niagen Plus Facebook
Niagen Plus Facebook
Niagen Plus on X
Niagen Plus on X
More from Linktree
Products
Link in bio + tools
Manage your social media
Grow and engage your audience
Monetize your following
Measure your success
Templates
Marketplace
Learn
Resources
How to use Linktree
Pricing
Link in bio + tools
Link in bio
Customize your Linktree
Link shortener
Create trackable, shareable short links
QR code generator
Turn links into scannable QR codes
Canva Background Editor
Import your custom designs from Canva into your profile
Linktree for every social platform
Grow and engage your audience everywhere
Instagram
TikTok
LinkedIn
X
Manage your social media
Schedule and auto-post
Hands-free, hassle-free social media planning
Instagram auto reply
Automated replies and DMs triggered by comments
AI content & caption generator
Instant AI-powered post ideas and captions
Hashtag generator
Trending hashtag suggestions for better reach
Social integration for every social platform
Plan, auto post, and share across all platforms
Instagram
TikTok
Facebook
Pinterest
LinkedIn
Threads
Youtube
Grow and engage your audience
Collect leads with contact forms
Turn visitors into subscribers
Manage and activate your audience
Organize, tag, and track contacts
Send contacts to email tools
Sync with Mailchimp, Klaviyo, Kit & more
Monetize your following
Earn with a Linktree Shop
Sell products and earn commission
Sell an online course
Create and sell your expertise easily
Host digital products
Sell digital products and build your email list
Earn by hosting sponsored links
Share brand offers and earn for every sign-up or sale
Get rewarded for growing your Linktree
Earn points, level up and unlock cash bonuses
Booked and paid, easily
Offer sessions and earn from your expertise
Measure your success
Social + link analytics
Track clicks, engagement and audience insights
Resources
Read our blog
All the latest tips, tricks and growth strategies
Success Stories
Real people, real results on Linktree
How to use Linktree
Linktree Help Centre
Get answers, guides and support